Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Science 359, 11511156
10.3390/nu13082750 51 TakayaK.SuzukiT.MotohashiH.OnoderaK.SatomiS.KenslerT
Anika Rao, MD, Board-Certified Internal Medicine
In 2024, results from the extended SURMOUNT-1 program showed that pooled tirzepatide doses reduced the risk of progression to type 2 diabetes by 94 percent in adults with prediabetes and obesity or overweight over 176 weeks, and nearly 99 percent of treated participants remained diabetes-free at that time point
At the center of this process lies a highly conserved enzyme: cytochrome P450 family 51 subfamily A member 1 (CYP51A1)
